EZH2 and cancer: In the present study, pan-cancer expression and survival analyses were performed on EZH2 using TCGA datasets, and we found that EZH2 was abnormally expressed in 15 types of cancer, including BLCA, BRCA, CESC, CHOL, COAD, GBM, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, READ, STAD, and UCEC.